CN101252931A - 用于治疗癌症的4-苯胺基-3-喹啉甲腈 - Google Patents

用于治疗癌症的4-苯胺基-3-喹啉甲腈 Download PDF

Info

Publication number
CN101252931A
CN101252931A CNA2006800223605A CN200680022360A CN101252931A CN 101252931 A CN101252931 A CN 101252931A CN A2006800223605 A CNA2006800223605 A CN A2006800223605A CN 200680022360 A CN200680022360 A CN 200680022360A CN 101252931 A CN101252931 A CN 101252931A
Authority
CN
China
Prior art keywords
cancer
pharmaceutically acceptable
chemical compound
acceptable salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800223605A
Other languages
English (en)
Chinese (zh)
Inventor
F·C·博谢利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37575124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101252931(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of CN101252931A publication Critical patent/CN101252931A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2006800223605A 2005-06-24 2006-06-13 用于治疗癌症的4-苯胺基-3-喹啉甲腈 Pending CN101252931A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69367105P 2005-06-24 2005-06-24
US60/693,671 2005-06-24

Publications (1)

Publication Number Publication Date
CN101252931A true CN101252931A (zh) 2008-08-27

Family

ID=37575124

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800223605A Pending CN101252931A (zh) 2005-06-24 2006-06-13 用于治疗癌症的4-苯胺基-3-喹啉甲腈

Country Status (20)

Country Link
US (1) US20070010527A1 (enExample)
EP (1) EP1893209A2 (enExample)
JP (1) JP2008546777A (enExample)
KR (1) KR20080027275A (enExample)
CN (1) CN101252931A (enExample)
AR (1) AR057403A1 (enExample)
AU (1) AU2006262591A1 (enExample)
BR (1) BRPI0611977A2 (enExample)
CA (1) CA2610209A1 (enExample)
CR (1) CR9539A (enExample)
EC (1) ECSP078015A (enExample)
GT (1) GT200600268A (enExample)
IL (1) IL187792A0 (enExample)
MX (1) MX2007016542A (enExample)
NI (1) NI200700323A (enExample)
NO (1) NO20076075L (enExample)
PE (1) PE20070323A1 (enExample)
RU (1) RU2007143434A (enExample)
TW (1) TW200730177A (enExample)
WO (1) WO2007001839A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007148072A (ru) * 2005-07-01 2009-08-10 Вайет (Us) Кристаллические формы 4-[(2,4-дихлор-5-метоксифинил)амино]-6- меокси-7-[3-(4-метил-1-пиперазинил)пропокси]-3-хиналинкарбонитрил и способы их получения
WO2013187967A1 (en) 2012-06-15 2013-12-19 Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control
WO2017134679A1 (en) * 2016-02-03 2017-08-10 Msn Laboratories Private Limited Novel crystalline polymorphs of 4-[(2.4-dichioro-5-methoxvphenvl)aniinol- 6-methoxv-7-13-(4-methyl-l-piperazinvl)propoxvl-3-quinolinecarbonitrile and process for preparation thereof
CN107433391B (zh) * 2017-07-03 2020-01-17 武汉逸飞激光设备有限公司 一种基于图像识别的焊接校准方法及系统

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6432979B1 (en) * 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
US6384051B1 (en) * 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
RU2006113691A (ru) * 2003-11-06 2007-12-20 Вайет (Us) Применение 4-анилин-3-хинолинкарбонитрилов для лечения хронической миелогенной лейкемии (cml)

Also Published As

Publication number Publication date
NO20076075L (no) 2008-03-18
MX2007016542A (es) 2008-03-04
IL187792A0 (en) 2008-11-03
CR9539A (es) 2008-02-20
NI200700323A (es) 2008-06-25
WO2007001839A2 (en) 2007-01-04
AU2006262591A1 (en) 2007-01-04
WO2007001839A3 (en) 2007-04-26
ECSP078015A (es) 2008-01-23
JP2008546777A (ja) 2008-12-25
EP1893209A2 (en) 2008-03-05
PE20070323A1 (es) 2007-05-04
AR057403A1 (es) 2007-12-05
US20070010527A1 (en) 2007-01-11
KR20080027275A (ko) 2008-03-26
BRPI0611977A2 (pt) 2010-10-13
RU2007143434A (ru) 2009-07-27
GT200600268A (es) 2007-06-18
TW200730177A (en) 2007-08-16
CA2610209A1 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
Kwan et al. The path to the clinic: a comprehensive review on direct KRASG12C inhibitors
JP6963146B1 (ja) 癌を治療するためのｋｒａｓ阻害剤の投与
US7919625B2 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
Gable et al. Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth
KR102857219B1 (ko) 암의 치료 또는 예방용 의약
JP2011046716A (ja) 癌の処置方法およびその関連方法
CN101410108B (zh) 用于治疗特定耐药性肿瘤的激酶抑制剂的应用
TW200811185A (en) Fused pyrimidones and thiopyrimidones, and uses thereof
Hamilton et al. Targeting of SOS1: from SOS1 activators to proteolysis targeting chimeras
CN107296807A (zh) Malt1靶向抑制物在制备malt1依赖性肿瘤治疗药物中的应用
CN101252931A (zh) 用于治疗癌症的4-苯胺基-3-喹啉甲腈
JP2023528945A (ja) Ｆｒｓ２－ｆｇｆｒ相互作用の小分子阻害剤、並びに医薬における、がんの予防及び治療における、その使用
JP2023507816A (ja) がんを治療するための方法及び組成物
WO2023105008A1 (en) Small-molecule inhibitors of the frs2-fgfr interaction
Khatri et al. Identification of alkynyl nicotinamide HSN748 as a RET solvent-front mutant inhibitor with intracranial efficacy
AU2020374269A1 (en) Novel heterocyclic-substituted pyrimidine derivative exhibiting cancer cell growth inhibitory effect, and pharmaceutical composition containing same
EP1883403A2 (en) Keratinocyte growth factor receptor - tyrosine specific inhibitors for the prevention of cancer metastatis
US20230212124A1 (en) Small-molecule inhibitors of the frs2-fgfr interaction
WO2008064004A2 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
WO2008060283A1 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
US20080119463A1 (en) 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
Chang HI-511 inhibits both BRAF and AURKB to overcome malignant melanoma drug resistance and metastasis
CN118574632A (zh) 癌的治疗或预防用药物
TW201217341A (en) Receptor-type kinase modulator and methods of treating polycystic kidney disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080827